Barclays lowered the firm’s price target on Moderna (MRNA) to $40 from $45 and keeps an Equal Weight rating on the shares following the Q1 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna’s Q1 2025: Revenue Decline and Strategic Focus
- Moderna’s Earnings Call: Progress Amid Challenges
- Moderna price target lowered to $28 from $32 at RBC Capital
- Moderna’s Strategic Shift Amidst Financial Challenges and Market Uncertainties: Analyst Maintains Hold Rating with Adjusted Target Price
- Moderna price target lowered to $32 from $40 at Citi